ClinicalTrials.gg
Active, not recruitingNCT05784012RADIANUpdated Jun 4, 2026

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

A Phase 1/2 interventional study of Dostarlimab and Niraparib in Head and Neck Squamous Cell Carcinoma, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Active, not recruiting at 7 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.

Enrollment
145th of 161
34 · median 160
Started
2023
with 16 others
Phase 1/2
33 of 167
11 open now
Primary completion
2027-03
later than 22 of 69 live
Registered
126th of 167
by date
Lead sponsor
4 of 167
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is the 145th largest by enrollment of the 161 interventional ones that give a count, is one of 17 that started in 2023, is one of 33 in phase 1/2, reaches primary completion later than 22 of the 69 other live ones, and was the 126th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, or all of them as a file.
02

Study summary

Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th TNM/AJCC ed.) and oral cavity (unresectable, stage IVB according to 8th TNM/ American Joint Committee on Cancer (AJCC) ed.) who are candidates for definitive radiotherapy plus cisplatin (Cohort A) or as single-modality (in cisplatin unfit patient population) (Cohort B) and will receive dostarlimab and niraparib in combination pre-, during and post- radiation.

Study has three parts:

  1. Neoadjuvant phase (immune-conditioning phase): patients will receive 1 dose of dostarlimab day -21; niraparib from day -14 prior to radiotherapy (up to 48h prior to radiotherapy (RT) in Cohort A; Cohort B niraparib is uninterrupted until the end of study treatment).
  2. Concurrent phase (radiosensitization): patients will receive definitive radiotherapy (70Gy in 35 fractions) with concurrent cisplatin (Cohort A) or with concurrent niraparib (Cohort B).
  3. Maintenance: Following radiotherapy, patients will receive adjuvant dostarlimab plus niraparib until Cycle 14 day1(dostarlimab) and day21(niraparib).
03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • non-metastatic
  • Oropharyngeal carcinoma
  • Laryngeal or hypopharyngeal carcinomas
  • Oral carcinoma
  • squamous cell carcinoma
  • radiotherapy
  • antiPD-1
  • PARP inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written and voluntary informed consent.
  2. Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  3. Age ≥ 18 years, male or female.

    Disease characteristics

  4. Have confirmed new diagnosis of non- squamous cell carcinoma as assessed by the Investigator based on baseline imaging and clinical assessment that is either:

    1. Stage III HPV-related oropharyngeal carcinoma OR
    2. Stage III, IVA and IVB HPV-unrelated oropharyngeal, laryngeal or hypopharyngeal carcinomas. Stage IVB oral cavity squamous cell carcinomas may be eligible upon consultation with Sponsor if considered unresectable as per treating surgeon and multidisciplinary tumor board.

      • According to UICC/AJCC 8th Edition staging
  5. Human papillomavirus (HPV)-relatedness in oropharyngeal primaries must be determined by positive p16 immunohistochemical staining on any tumor specimens and, if positive, confirmed by human papilloma virus (HPV) DNA testing by in situ hybridisation (ISH) or polymerase chain reaction (PCR). Positive p16 expression is defined as strong and diffuse nuclear and cytoplasmic staining in 70 % or more of the tumor cells. Local testing is acceptable.
  6. Patients must have positive expression (CPS ≥ 1) by central laboratory (using PD-L1 immunohistochemistry [IHC] 22C3 pharmDx assay) on .
  7. Have an evaluable tumor burden assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on 1.1 as assessed by the local site investigator/radiology.
  8. Have provided newly obtained core or excisional biopsy of a tumor lesion not previously irradiated for central biomarker analysis (fine needle aspirate (FNA) is not adequate).

    Repeat samples may be required if adequate tissue is not provided. Formalin-fixed, paraffin embedded tissue blocks are preferred to slides.

    Patient characteristics

  9. (ECOG) performance status 0-1.
  10. Patient must have adequate organ function as determined by the following:

    a. Hematology i. Absolute neutrophils > 1.5 x 109/L ii. > 100 x 109/L iii. > 90 g/L b. Biochemistry i. \< 1.5 x (ULN) ii. (AST) and alanine transaminase (ALT) \< 2.5 x ULN iii. Plasmatic albumin ≥ 3.0 g/dL Note: Hematology test should be obtained without transfusion or receipt of colony stimulating factors within 4 weeks prior to obtaining sample.

    Specific criteria for Cohort A:

    iv. ≥ 60 mL/min as per cockcroft -gault formula v. Not presenting with peripheral neuropathy ≥ grade 2 ( v5.0). vi. Not presenting with clinically-significant hearing loss/tinnitus (≥ grade 3 by CTCAE v5.0).

    vii. 18-69 years old (Patients ≥ 70 years old only eligible for cohort B) viii. Not presenting with cardiovascular disease: new york health association () class II or higher, ischemic cardiovascular/cerebrovascular event in the past 12 months prior to inclusion in the study, clinically-significant peripheral arterial vasculopathy

    Specific criteria for Cohort B c. Patients considered unfit for cisplatin-based chemoradiotherapy, based on the following criteria (at least one): i. Creatinine clearance ≥30 but \<60 mL/min ii. Impaired hearing loss/tinnitus (≥ grade 3 by CTCAE v5.0). iii. Peripheral neuropathy ≥ grade 2 (CTCAE v5.0). iv. Age ≥ 70 years old * Patients ≥ 70 years old must be fit according to the G8 geriatric screening test (G8 > 14 points)

  11. Evidence of status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    1. Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
    2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  12. Female subjects of must use effective during therapy and for up to 180 days after receiving the last dose of niraparib or for 150 days after the last dose of dostarlimab.
  13. Male patients with a female partner of childbearing potential:

    • Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 150 days after receipt of the last dose of dostarlimab and/or 90 days after receipt of niraparib therapy whichever occurs later.
    • Not engaging in sexual activity from screening through 150 days after receipt of the last dose of dostarlimab and/or 90 days after receipt of niraparib ( whichever occurs later) is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Throughout this period, male patients should refrain from sperm donation, and female patients should refrain from egg cell donation.
    • Female partners (of childbearing potential) of male patients must also use a highly effective method of contraception throughout this period

Exclusion criteria

Exclusion Criteria:

  1. Early stages, defined as stage I-II according to Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) 8th Edition staging in any localization, and including HPV-related and non-related.
  2. Stage III-IVA oral cavity carcinoma considered resectable as per treating surgeon and/or multidisciplinary tumor board.
  3. Has cancer outside of the oropharynx, larynx, and hypopharynx and oral cavity.
  4. Current history of other head and neck .
  5. Any previous treatment for current head and neck cancer including systemic therapy, radiotherapy and/or surgery (except for a diagnostic ) and no major surgery within 28 days prior to study treatment initiation.
  6. Any previous radiation to the head and neck region that would result in overlap of fields for the current study.
  7. Patients unable to swallow niraparib tablets.
  8. Documented weight loss of >10 % during the last 4 weeks prior to study treatment initiation (unless adequate measures are undertaken for nutritional support), OR plasmatic albumin \< 3.0 g/dL. No albumin transfusions are allowed within 2 weeks before study treatment initiation.
  9. Active gastrointestinal bleeding, or any other uncontrolled bleeding requiring more than 2 red blood cell transfusions or 4 units of packed red blood cells within 4 weeks prior to study treatment initiation.
  10. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take niraparib.
  11. History of primary immunodeficiency, history of allogeneic organ transplant that requires therapeutic and the use of immunosuppressive agents within 28 days of study treatment initiation or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy or grade ≥ 3 infusion reaction.
  12. Active or prior documented or inflammatory disorders (including inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the exception of diverticulosis, celiac disease (controlled by diet alone) or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment. The following are exceptions to this criterion: vitiligo or alopecia; Patients with Grave's disease, vitiligo or psoriasis not requiring systemic treatment (within the last 2 years); Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement. Any chronic skin condition that does not require systemic therapy.
  13. History of interstitial lung disease e.g. pneumonitis requiring (any dose) or immunomodulatory treatment within 90 days before the planned start of the study therapy; or pulmonary fibrosis or evidence of pneumonitis on baseline CT scan.
  14. Any concurrent chemotherapy, biologic, immunologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable.
  15. Current or prior use of immunosuppressive medication within 14 days prior to starting dosing. The following are exceptions to these criteria:

    1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).
    2. Adrenal replacement steroid > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
    3. Steroids as premedication for reactions (eg, computed tomography scan premedication).
  16. Active or documented history of autoimmune disease within 2 years before screening, including:

    1. Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis).
    2. Patients with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, Grave's disease, Hashimoto's disease, or psoriasis not requiring systemic steroids and/or immunosuppressive agents within the past 2 years, are not excluded.
  17. History of stroke or within the previous 6 months.
  18. History of uncontrolled hypertension: systolic BP >140 mmHg or diastolic BP >90 mmHg that has not been adequately treated or controlled prior to Day 1 of protocol therapy.
  19. Any of the following cardiac abnormalities:

    1. Unstable angina pectoris,
    2. Congestive heart failure ≥ Class 2,
    3. >480 milliseconds. QTc calculation using Fridericia formula (ms)
    4. Known (LVEF) \< 50.
    5. Unstable cardiac arrhythmia
  20. Concomitant medication known to cause prolonged QT that cannot be discontinued or changed to a different medication prior to enrollment.
  21. Patients with prior history of posterior reversible encephalopathy syndrome (PRES)
  22. Known allergy or reaction to any components of niraparib and/or dostarlimab.
  23. Subjects who are human immunodeficiency () positive.
  24. Has a known history of or is positive for active (defined as hepatitis B surface antigen [HBsAg] reactive) or (defined as hepatitis C virus (HCV) RNA [qualitative] is detected).

    1. hepatitis B virus (HBV) DNA must be undetectable and HBsAg negative at Screening Visit.
    2. Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at Screening Visit.
  25. Female patients who are pregnant or breast-feeding. Women of should not become pregnant while on treatment and should not be pregnant at the beginning of treatment.
  26. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics 2 weeks before treatment start, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events from niraparib and/or dostarlimab, or compromise the ability of the subject to give written .
  27. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results.
  28. History of another primary malignancy, except for:

    1. Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study drug and of low potential risk for recurrence,
    2. Adequately treated non-melanoma skin cancer without evidence of disease,
    3. Adequately treated carcinoma in situ without evidence of disease.
  29. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study medications. Scheduled PEG implantation and planned tracheostomy are not considered major surgery.
  30. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1.
  31. Any malabsorption problem that, in the investigator's opinion, would prevent adequate absorption of the study drug.
  32. Known history of myelodysplastic syndrome (MDS) or a pre-treatment cytogenetic testing result at risk for a diagnosis of MDS/acute myeloid leukemia (AML).
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cohort A

    Three stages: Neoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until 48 hours prior to the start of definitive radiotherapy (day 0). Concurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday) with concurrent Cisplatin at a dose of 100 mg/m2 intravenously on day 1 of week 1, week 4 and week 7. Maintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily at a dose of 200 or 300 mg in cycles of 21 days.

    Drug: Dostarlimab · Drug: Niraparib · Drug: cisplatin plus radiotherapy

  • Experimental
    Cohort B

    Three stages: Neoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until the start of definitive radiotherapy (day 0). Concurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday). Niraparib is to be given once daily on a continous basis (200 to 300 mg), from w1 d1 until end of w10 in cycles of 21 days. Maintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily on a continous basis at a dose of 200 or 300 mg in cycles of 21 days.

    Drug: Dostarlimab · Drug: Niraparib

Interventions

  • Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.

  • Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.

  • Drugcisplatin plus radiotherapy

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In the concurrent phase

  • Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).

06

What researchers measure

Primary outcomes

  1. 1-year disease free survival

    Disease-free survival (DFS) is defined as the time from the date of study treatment initiation to the date of first record of any of the following events: Investigator determined: Locoregional progression or recurrence. Distant metastasis. Neck dissection or surgery performed for clinical or radiological disease progression (RECIST 1.1) \> 20 weeks from the end of radiation therapy with tumor present on final pathology. Death due to any cause. Patients not presenting any of the previous events will be censored at the date of last assessment.

    Time frame: 1 year after the start of the study treatment

Secondary outcomes

  1. Disease control rate

    Disease Control Rate (DCR) is defined as the percentage of patients who have achieved complete response, partial response and stable disease by RECIST 1.1 at a certain time point. DCR will be evaluated at 12, 18 and 24 and 36 months.

    Time frame: Throughout the study period, approximately 36 months

  2. Locoregional control

    Time to locoregional failure is defined as the time from the date of study treatment initiation to the date of the first record of appearance of local or regional progression/recurrence, to the date of neck dissection \> 20 weeks performed for clinical or radiological (RECIST 1.1) disease progression from the end of radiation therapy with tumor present, or to the date of surgery of primary tumor with tumor present performed for clinical or radiological (RECIST 1.1) disease progression, whichever comes first.

    Time frame: Throughout the study period, approximately 36 months

  3. Distant control

    Time to distant metastasis is defined as the time from the date of study treatment initiation to the date of first record of appearance of distant metastasis. Locoregional failure or second cancers diagnosed before the distant metastases are not considered events of interest for this endpoint.

    Time frame: Throughout the study period, approximately 36 months

  4. Event-free survival

    Event-free survival (EFS) is defined as the time from the date of study treatment initiation to the date of first record of any of the following events: Investigator determined: Locoregional progression or recurrence. Distant metastasis. Surgery: Surgery for persistent or residual disease at the primary tumor site with tumor present on final pathology. Neck dissection or surgery performed for clinical or radiological disease progression (RECIST 1.1) \> 20 weeks from the end of radiation therapy with tumor present on final pathology. Death due to any cause. Patients not presenting any of the previous events will be censored at the date of last assessment.

    Time frame: Throughout the study period, approximately 36 months

  5. Overall survival

    Event-free survival (EFS) is defined as the time from the date of study treatment initiation to the date of first record of any of the following events: Investigator determined: Locoregional progression or recurrence. Distant metastasis. Surgery: Surgery for persistent or residual disease at the primary tumor site with tumor present on final pathology. Neck dissection or surgery performed for clinical or radiological disease progression (RECIST 1.1) \> 20 weeks from the end of radiation therapy with tumor present on final pathology. Death due to any cause. Patients not presenting any of the previous events will be censored at the date of last assessment.

    Time frame: Throughout the study period, approximately 36 months

  6. Frequency of treatment-related adverse events

    Number of patient who experienced treatment-related adverse events (AEs)

    Time frame: Throughout the study period, approximately 36 months

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Mar 2027, 40 months after the start.

Of 45 non-industry phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 83. This study's planned 40 months is below that.

Counting every sponsor, half of 137 studies reached it within 61 months; a quarter within 47 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Nov 13, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2029
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05784012
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Collaborators
GlaxoSmithKline, MFAR
Responsible party
Sponsor
First posted
Mar 24, 2023
Start date
Nov 13, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 4, 2026

Study contacts

Marc Oliva, M.D. PhD
study chair · Institut Català D´Oncologia (ICO) Hospitalet de Llobregat
Ricard Mesia, M.D. Ph.D.
study chair · Institut Català d''Oncologia (ICO) Badalona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Niraparib

Start the discussion